StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Earnings

Kyverna Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.68
-$0.85 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Kyverna Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open––-$0.68Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026during market hours––-$0.63Release
Q1 FY2026ended Mar 31, 2026May 12, 2026during market hours––-$0.66Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026during market hours––-$0.80Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025during market hours––-$0.85Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025during market hours––-$0.97Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours––-$1.03Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024during market hours––-$0.67Release
Q1 FY2024ended Mar 31, 2024May 14, 2024during market hours––-$1.12Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Kyverna Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Kyverna Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Kyverna Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Update
  5. News
  6. Results
  7. News
  8. Update
  9. Update
  10. Update
  11. Results
  12. News
  13. News
  14. Results
  15. News

See a number that looks wrong?